China Medical System (HKG:0867, SGX:8A8), through its units, entered an agreement with Novartis Pharma Services to distribute Lucentis and Beovu, a Monday Hong Kong bourse filing said.
Under the contract, the pharma firm will import, distribute, sell, and promote the products in China, excluding Hong Kong, Macao, and Taiwan, for five years.
Lucentis has been approved to treat multiple ocular neovascular diseases in China since 2011, while Beovu is approved to treat diabetic macular edema.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.